PharmaPoint: Dry Eye Syndrome - Current and Future Players

Published: May 2013
No. of Pages: 45
   

PharmaPoint: Dry Eye Syndrome - Current and Future Players

Summary

GlobalData has released its pharma report, “PharmaPoint: Dry Eye Syndrome - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing DES Market. The report identifies and analyses the key companies shaping and driving the global DES market. The report provides insight into the competitive DES landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.


Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation.

Scope

- Investigation of current and future market competition for DES
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of DES sector through market impact analysis, future market scenario and company analysis.

Reasons to buy

- Gain a high level view of the trends shaping and driving DES Market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What’s the next big thing in the global DES market landscape? Identify, understand and capitalize.

PharmaPoint: Dry Eye Syndrome - Current and Future Players

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
3 Market Outlook 9
3.1 Global Markets 9
3.1.1 Forecast 9
3.1.2 Drivers and Barriers – Global Issues 11
4 Current and Future Players 14
4.1 Overview 14
4.2 Trends in Corporate Strategy 16
4.3 Company Profiles 17
4.3.1 Allergan 17
4.3.2 Alcon (a wholly-owned subsidiary of Novartis AG) 19
4.3.3 Santen Pharmaceutical 22
4.3.4 Shire/SARcode Bioscience 25
4.3.5 Otsuka Holdings 27
4.3.6 Can-Fite Biopharma 29
4.3.7 Eyegate Pharma 30
5 Appendix 32
5.1 Bibliography 32
5.2 Abbreviations 33
5.3 Methodology 34
5.4 Forecasting Methodology 34
5.4.1 Diagnosed DES patients 34
5.4.2 Percent Drug-treated Patients 35
5.4.3 Drugs Included in Each Therapeutic Class 35
5.4.4 Launch and Patent Expiry Dates 35
5.4.5 General Pricing Assumptions 36
5.4.6 Individual Drug Assumptions 37
5.4.7 Generic Erosion 41
5.5 Physicians and Specialists Included in this Study 42
5.6 About the Authors 43
5.6.1 Author 43
5.6.2 Global Head of Healthcare 44
5.7 About GlobalData 45
5.8 Contact Us 45
5.9 Disclaimer 45

1.1 List of Tables
Table 1: Global Sales Forecasts ($m) for Dry Eye Syndrome, 2012–2022 10
Table 2: Dry Eye Syndrome Global Market – Drivers and Barriers, 2012–2022 11
Table 3: Key Companies in the Dry Eye Syndrome Market, 2012 15
Table 4: Allergan’s Dry Eye Syndrome Portfolio Assessment, 2012 18
Table 5: Allergan SWOT Analysis, 2012 19
Table 6: Alcon’s Dry Eye Syndrome Portfolio Assessment, 2012 20
Table 7: Alcon’s Dry Eye Syndrome Portfolio SWOT Assessment, 2012 21
Table 8: Santen Pharmaceutical’s Dry Eye Syndrome Portfolio Assessment, 2012 22
Table 9: Santen Pharmaceutical’s Dry Eye Syndrome Portfolio Assessment, 2012 24
Table 10: Santen Pharmaceutical’s Dry Eye Syndrome Portfolio SWOT Analysis, 2012 25
Table 11: Shire’s Dry Eye Syndrome Portfolio Assessment, 2013 26
Table 12: Shire’s Dry Eye Syndrome Portfolio SWOT Analysis, 2013 26
Table 13: Otsuka Pharmaceutical’s Dry Eye Syndrome Portfolio Assessment, 2012 28
Table 14: Otsuka Pharmaceutical’s Dry Eye Syndrome Portfolio SWOT Analysis, 2012 28
Table 15: Can-Fite Dry Eye Syndrome Portfolio Assessment, 2012 29
Table 16: Can-Fite’s Dry Eye Syndome Portfolio SWOT Analysis, 2012 30
Table 17: Eyegate Pharma’s Dry Eye Syndrome Portfolio Assessment, 2012 31
Table 18: Eyegate Pharma’s Dry Eye Syndrome Portfolio SWOT Analysis, 2012 31
Table 19: Key Launch Dates 35
Table 20: Key Patent Expiries 35

1.2 List of Figures
Figure 1: Global Sales for Dry Eye Syndrome by Region, 2012–2022 11
Figure 2: Company Portfolio Gap Analysis in Dry Eye Syndrome, 2012–2022 16

Published By: GlobalData
Product Code: GlobalData27978


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we’ll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest:

Live Chat
Live Chat by Comm100